BNP Paribas Financial Markets Sells 53,308 Shares of Liquidia Co. (NASDAQ:LQDA)

BNP Paribas Financial Markets reduced its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 38.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,882 shares of the company’s stock after selling 53,308 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.10% of Liquidia worth $1,022,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Liquidia by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock valued at $41,834,000 after acquiring an additional 115,367 shares in the last quarter. LM Advisors LLC purchased a new position in Liquidia during the 4th quarter valued at about $25,948,000. Geode Capital Management LLC raised its holdings in shares of Liquidia by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock valued at $15,753,000 after purchasing an additional 101,597 shares in the last quarter. Invesco Ltd. lifted its position in shares of Liquidia by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock worth $8,234,000 after purchasing an additional 674,940 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Liquidia by 19.5% during the fourth quarter. Northern Trust Corp now owns 589,921 shares of the company’s stock valued at $6,937,000 after purchasing an additional 96,381 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Price Performance

Shares of LQDA stock opened at $17.02 on Wednesday. The business’s fifty day moving average price is $14.67 and its 200 day moving average price is $13.48. The firm has a market capitalization of $1.45 billion, a PE ratio of -10.44 and a beta of 0.24. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $19.41.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million for the quarter, compared to analysts’ expectations of $3.23 million. Equities research analysts expect that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Oppenheimer lowered shares of Liquidia from a “market perform” rating to an “underperform” rating and set a $13.00 price objective for the company. in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Liquidia in a research report on Monday, May 12th. Raymond James increased their price objective on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Monday, May 12th. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.56.

Insider Transactions at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now directly owns 1,006,420 shares of the company’s stock, valued at $13,657,119.40. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,138 shares of company stock worth $450,233 over the last quarter. 26.50% of the stock is currently owned by insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).